First Add-on vs. Mono-therapy Study of Topiramate in Neuro-Surgical Patients (TEAMS)

Topiramate in the Treatment of Epilepsy: 1st Add-on vs. Mono-therapy Study in Neuro-Surgical Patients

The purpose of this study is to examine seizure control and tolerability of Topiramate after either transitioning from previous antiepileptic drug (AED) or adding on to previous AED.

Study Overview

• Status: Completed
• Conditions: Epilepsy
• Intervention / Treatment: Drug: Topiramate add-on therapy; Drug: Topiramate monotherapy

Detailed Description

This is a multicenter, randomized (treatment is assigned by chance), open-label (everyone who is involved in the trial knows the study drug), parallel group trial. The study has three phases: a retrospective baseline assessment of patients (4 weeks), titration period (8 weeks) and maintenance period (8 weeks). After qualifying for trial entry in the retrospective baseline phase, eligible patients will be randomized in 1:1 ratio to receive either topiramate add-on therapy or topiramate monotherapy. During the titration period (period in which the dose of the study drug is increased or decreased at the discretion of investigator), topiramate, given as morning doses, will be started with daily doses of 25 mg/day for one week. After that, topiramate will be given as morning and evening doses, and the doses will be gradually increased every week to reach the initial target dose of 200 mg/day at the end of titration period. During the maintenance period, the dose of topiramate could be increased or decreased according to the investigator's judgment. Patients should keep seizure diaries during the 16 weeks of topiramate treated period and are followed with once monthly visits to the clinic, at which safety will be evaluated.

• Study Type: Interventional
• Enrollment (Actual): 55
• Phase: Phase 4

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Must be diagnosed with seizure disorder
• Have been receiving concomitant therapy with one antiepileptic drug (AED), at stable dose prior to trial entry
• Must be dissatisfied with the current treatment

Exclusion Criteria:

• Have treatable cause of seizures (eg, metabolic disturbance, toxic exposure, an active infection, or neoplasm)
• Have grade IV astrocytomas, eg, Glioblastoma multiforme (GBM) or metastases with progression
• Have seizures occurring only in clustered patterns defined as numerous seizures occurring in less than 30 min
• Have had history (within past six months) of a psychiatric or mood disorder requiring electroconvulsive therapy, major tranquilizers, or monoamine oxidase inhibitors
• Have had schizophrenic or history of exhibiting psychotic symptomatology
• Inability to take medication or maintain a seizure calendar, independently or with assistance

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Topiramate add-on therapy	Drug: Topiramate add-on therapy; Type=range, unit=mg/day, number=25-200, form=tablet, route=oral use.
Experimental: Topiramate monotherapy	Drug: Topiramate monotherapy; Type= range, unit= mg/day, number= 25-200, form= tablet, route= oral use.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Seizure Free Rate: Percentage of Participants Who Did Not Have Any Seizure Episode Within the Last Month of the Maintenance Period (ie, Month 4).	Month 4

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Seizure Frequency: Percent Change of Seizure Frequency by the ANCOVA Model During the Month 4	Seizure frequency (seizure count/month) was calculated based on the number of seizure within a month. The mean seizure frequency analyzed by the ANCOVA model at each period.	Baseline (4 weeks retrospective assessment prior to start of titration period) to Month 4
Dosage Administration of Topamax During Month 4		Month 4

Collaborators and Investigators

• Sponsor: Johnson & Johnson Taiwan Ltd
• Investigators: Study Director: Janssen-Cilag Taiwan Clinical Trial, Janssen-Cilag Taiwan

Study record dates

Study Major Dates

• Study Start: February 1, 2010
• Primary Completion (Actual): January 1, 2011
• Study Completion (Actual): January 1, 2011

Study Registration Dates

• First Submitted: May 31, 2012
• First Submitted That Met QC Criteria: June 22, 2012
• First Posted (Estimate): June 26, 2012

Study Record Updates

• Last Update Posted (Estimate): October 29, 2013
• Last Update Submitted That Met QC Criteria: September 24, 2013
• Last Verified: September 1, 2013

More Information

Terms related to this study

• Keywords: Epilepsy; Seizures; Topiramate; Nervous disorder; Neuro-surgical patients
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Epilepsy; Hypoglycemic Agents; Physiological Effects of Drugs; Anticonvulsants; Topiramate
• Other Study ID Numbers: CR017248; TOPMATEPY4061 (Other Identifier: Janssen-Cilag Taiwan); TOP-TWN-MA4 (Other Identifier: Janssen-Cilag Taiwan)